PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: PDSB) | Delayed: 1.16 -0.08 (6.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.24 | 52 Week High | $ | |||
| Open | $1.16 | 52 Week Low | $ | |||
| Day High | $1.22 | P/E | N/A | |||
| Day Low | $1.12 | EPS | $ | |||
| Volume | 5,119,255 | |||||
